{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:35:39Z","timestamp":1790796939564,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To evaluate the long-term efficacy and safety of fremanezumab over a 2-year period in a real-world setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective, observational, single-center cohort study included 165 patients with episodic migraine (EM) or chronic migraine (CM) who received fremanezumab treatment. The primary endpoint was the change in monthly migraine days (MMDs) from baseline to months 1\u201324. The secondary endpoints included changes in Migraine Disability Assessment (MIDAS) scores, adverse events, response rates, predictors for responders, and treatment persistence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the entire cohort, the MMD changes from baseline at 3, 6, 12, and 24\u00a0months were \u2009\u2212\u20097.2\u2009\u00b1\u20094.7, \u2009\u2212\u20098.1\u2009\u00b1\u20096.3, \u2009\u2212\u20098.4\u2009\u00b1\u20095.1, and \u2009\u2212\u20099.6\u2009\u00b1\u20096.0\u00a0days, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). After 3, 6, 12, and 24\u00a0months, the\u2009\u2265\u200950% response rates were 57.0%, 63.6%, 63.5%, and 69.0%, respectively. The MIDAS score significantly decreased in the total sample and the EM and CM groups. No significant difference in efficacy was found between the monthly and quarterly dosing groups. Adverse events, mainly injection site reactions, occurred in 13.3% of the patients, and 2.4% of the participants discontinued treatment due to side effects. There were different clinical backgrounds between non-responders, and early and ultra-late responders, including psychiatric complications, medication overuse headache, and pulsatile headache. The treatment continuation rates at 12, 18, and 24\u00a0months were 73.5%, 65.4%, and 58.0%, respectively, with higher persistence in patients who received quarterly dosing than in those who received monthly dosing (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Fremanezumab is effective and well tolerated for long-term migraine prophylaxis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s42466-025-00395-y","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T14:54:11Z","timestamp":1748962451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14\u00a0months"],"prefix":"10.1186","volume":"7","author":[{"given":"Shiho","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0320-8993","authenticated-orcid":false,"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukuto","family":"Shioda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"10283","key":"395_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina, M., Katsarava, Z., Do, T. P., Buse, D. C., Pozo-Rosich, P., Ozge, A., Krymchantowski, A. V., Lebedeva, E. R., Ravishankar, K., Yu, S., Sacco, S., Ashina, S., Younis, S., Steiner, T. J., & Lipton, R. B. (2021). Migraine: Epidemiology and systems of care. Lancet, 397(10283), 1485\u20131495. https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7","journal-title":"Lancet"},{"issue":"10100","key":"395_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD_2021_Diseases_and_Injuries_Collaborators","year":"2017","unstructured":"GBD_2021_Diseases_and_Injuries_Collaborators. (2017). GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390(10100), 1211\u20131259. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2","journal-title":"Lancet"},{"key":"395_CR3","doi-asserted-by":"publisher","first-page":"1032103","DOI":"10.3389\/fneur.2022.1032103","volume":"13","author":"M Vincent","year":"2022","unstructured":"Vincent, M., Viktrup, L., Nicholson, R. A., Ossipov, M. H., & Vargas, B. B. (2022). The not so hidden impact of interictal burden in migraine: A narrative review. Frontiers in Neurology, 13, 1032103. https:\/\/doi.org\/10.3389\/fneur.2022.1032103","journal-title":"Frontiers in Neurology"},{"issue":"5","key":"395_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/head.14693","volume":"64","author":"J Robblee","year":"2024","unstructured":"Robblee, J., Hakim, S. M., Reynolds, J. M., Monteith, T. S., Zhang, N., & Barad, M. (2024). Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials. Headache, 64(5), 547\u2013572. https:\/\/doi.org\/10.1111\/head.14693","journal-title":"Headache"},{"key":"395_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14090948","author":"B Orlando","year":"2024","unstructured":"Orlando, B., Egeo, G., Aurilia, C., Fiorentini, G., & Barbanti, P. (2024). Calcitonin gene-related peptide monoclonal antibodies: Key lessons from real-world evidence. Brain Science. https:\/\/doi.org\/10.3390\/brainsci14090948","journal-title":"Brain Science"},{"issue":"2","key":"395_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","volume":"65","author":"M Romozzi","year":"2025","unstructured":"Romozzi, M., Munafo, A., Burgalassi, A., De Cesaris, F., Vigani, G., Altamura, C., Rivi, V., Guerzoni, S., Calabresi, P., Raffaelli, B., & Iannone, L. F. (2025). Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review. Headache, 65(2), 342\u2013352. https:\/\/doi.org\/10.1111\/head.14903","journal-title":"Headache"},{"key":"395_CR7","doi-asserted-by":"publisher","first-page":"1220285","DOI":"10.3389\/fneur.2023.1220285","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki, S., Suzuki, K., Shiina, T., Haruyama, Y., & Hirata, K. (2023). Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Frontiers in Neurology, 14, 1220285. https:\/\/doi.org\/10.3389\/fneur.2023.1220285","journal-title":"Frontiers in Neurology"},{"issue":"5","key":"395_CR8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/ene.15740","volume":"30","author":"AA Argyriou","year":"2023","unstructured":"Argyriou, A. A., Dermitzakis, E. V., Xiromerisiou, G., Rallis, D., Soldatos, P., Litsardopoulos, P., & Vikelis, M. (2023). Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real-world data from a Greek registry. European Journal of Neurology, 30(5), 1435\u20131442. https:\/\/doi.org\/10.1111\/ene.15740","journal-title":"European Journal of Neurology"},{"issue":"1","key":"395_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti, P., Egeo, G., Aurilia, C., d\u2019Onofrio, F., Albanese, M., Cetta, I., Di Fiore, P., Zucco, M., Filippi, M., Bono, F., Altamura, C., Proietti, S., Bonassi, S., Vernieri, F., Group FR-S. (2022). Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). The Journal of Headache and Pain, 23(1), 46. https:\/\/doi.org\/10.1186\/s10194-022-01396-x","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"395_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s10194-023-01561-w","volume":"24","author":"P Barbanti","year":"2023","unstructured":"Barbanti, P., Egeo, G., Aurilia, C., Torelli, P., Finocchi, C., d\u2019Onofrio, F., d\u2019Onofrio, L., Rao, R., Messina, S., Di Clemente, L., Ranieri, A., Autunno, M., Sette, G., Colombo, B., Carnevale, A., Aguggia, M., Tasillo, M., Zoroddu, F., Frediani, F., \u2026 Group FR-S. (2023). Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. The Journal of Headache and Pain, 24(1), 30. https:\/\/doi.org\/10.1186\/s10194-023-01561-w","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"395_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-022-01415-x","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen, M. T., Cohen, J. M., Thompson, S. F., Patterson-Lomba, O., Seminerio, M. J., Carr, K., Totev, T. I., Sun, R., Yim, E., Mu, F., & Ayyagari, R. (2022). Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. The Journal of Headache and Pain, 23(1), 56. https:\/\/doi.org\/10.1186\/s10194-022-01415-x","journal-title":"The Journal of Headache and Pain"},{"issue":"3","key":"395_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40120-024-00591-z","volume":"13","author":"P Barbanti","year":"2024","unstructured":"Barbanti, P., Egeo, G., Proietti, S., d\u2019Onofrio, F., Aurilia, C., Finocchi, C., Di Clemente, L., Zucco, M., Doretti, A., Messina, S., Autunno, M., Ranieri, A., Carnevale, A., Colombo, B., Filippi, M., Tasillo, M., Rinalduzzi, S., Querzani, P., Sette, G., \u2026 Italian Migraine Registry study g. (2024). Assessing the long-term (48-week) effectiveness, safety, and tolerability of Fremanezumab in migraine in real life: insights from the multicenter, prospective, FRIEND3 Study. Neurol Ther, 13(3), 611\u2013624. https:\/\/doi.org\/10.1007\/s40120-024-00591-z","journal-title":"Neurol Ther"},{"issue":"12","key":"395_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40263-023-01050-3","volume":"37","author":"V Caponnetto","year":"2023","unstructured":"Caponnetto, V., Russo, A., Silvestro, M., Tessitore, A., De Icco, R., Vaghi, G., Sances, G., Tassorelli, C., Baraldi, C., Castro, F. L., Guerzoni, S., Prudenzano, M. P., Fallacara, A., Gentile, M., Ornello, R., Onofri, A., Burgalassi, A., Chiarugi, A., De Cesaris, F., \u2026 Italian Headache Registry Study G. (2023). Long-term treatment over 52 weeks with monthly fremanezumab in drug-resistant migraine: A prospective multicenter Cohort study. CNS Drugs, 37(12), 1069\u20131080. https:\/\/doi.org\/10.1007\/s40263-023-01050-3","journal-title":"CNS Drugs"},{"issue":"11","key":"395_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/pm\/pnae050","volume":"25","author":"S Kikui","year":"2024","unstructured":"Kikui, S., Daisuke, D., Miyahara, J., Sugiyama, H., Ota, K., Murakata, K., Kashiwaya, Y., & Takeshima, T. (2024). Effectiveness of fremanezumab treatment in patients with migraine headache. Pain Medicine, 25(11), 664\u2013670. https:\/\/doi.org\/10.1093\/pm\/pnae050","journal-title":"Pain Medicine"},{"issue":"11","key":"395_CR15","doi-asserted-by":"publisher","first-page":"333102423121498","DOI":"10.1177\/03331024231214987","volume":"43","author":"M Ashina","year":"2023","unstructured":"Ashina, M., Mitsikostas, D. D., Amin, F. M., Kokturk, P., Schankin, C. J., Sahin, G., Pozo-Rosich, P., Dorman, P. J., Nezadal, T., Poole, A. C., Martins, I. P., Sumelahti, M. L., Ramirez Campos, V., Ahn, A. H., Lyras, L., & Tassorelli, C. (2023). Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. Cephalalgia, 43(11), 3331024231214987. https:\/\/doi.org\/10.1177\/03331024231214987","journal-title":"Cephalalgia"},{"issue":"1","key":"395_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache_Classification_Committee_of_the_International_Headache_Society_(IHS)","year":"2018","unstructured":"Headache_Classification_Committee_of_the_International_Headache_Society_(IHS). (2018). The international classification of headache disorders. Cephalalgia, 38(1), 1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"5","key":"395_CR17","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","volume":"271","author":"P Barbanti","year":"2024","unstructured":"Barbanti, P., Aurilia, C., Egeo, G., Proietti, S., D\u2019Onofrio, F., Torelli, P., Aguggia, M., Bertuzzo, D., Finocchi, C., Trimboli, M., Cevoli, S., Fiorentini, G., Orlando, B., Zucco, M., Di Clemente, L., Cetta, I., Colombo, B., di Poggio, M. L. B., Favoni, V., \u2026 Ert, for the Italian Migraine Registry study g. (2024). Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: A multicenter, prospective, observational study. Journal of Neurology, 271(5), 2434\u20132443. https:\/\/doi.org\/10.1007\/s00415-023-12103-4","journal-title":"Journal of Neurology"},{"key":"395_CR18","doi-asserted-by":"publisher","first-page":"251581632312073","DOI":"10.1177\/25158163231207322","volume":"6","author":"S Suzuki","year":"2023","unstructured":"Suzuki, S., Suzuki, K., Shiina, T., Haruyama, Y., & Hirata, K. (2023). Evaluating the wearing-off effects of fremanezumab in high-frequency episodic migraine and chronic migraine: A real-world observational study in Japan. Cephalalgia Reports, 6, 25158163231207320. https:\/\/doi.org\/10.1177\/25158163231207322","journal-title":"Cephalalgia Reports"},{"issue":"1","key":"395_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s10194-025-01994-5","volume":"26","author":"S Yoshida","year":"2025","unstructured":"Yoshida, S., Imai, N., Keicho, M., Kamimura, J., Moriya, A., Yagi, N., Suzuki, R., Konishi, T., & Serizawa, M. (2025). Efficacy and continuability of 675 mg fremanezumab administration over 2 years. The Journal of Headache and Pain, 26(1), 51. https:\/\/doi.org\/10.1186\/s10194-025-01994-5","journal-title":"The Journal of Headache and Pain"},{"issue":"12","key":"395_CR20","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40264-021-01119-2","volume":"44","author":"F Sakai","year":"2021","unstructured":"Sakai, F., Suzuki, N., Ning, X., Ishida, M., Usuki, C., Iba, K., Isogai, Y., & Koga, N. (2021). Long-term safety and tolerability of fremanezumab for migraine preventive treatment in Japanese outpatients: A multicenter, randomized, open-label study. Drug Safety, 44(12), 1355\u20131364. https:\/\/doi.org\/10.1007\/s40264-021-01119-2","journal-title":"Drug Safety"},{"issue":"18","key":"395_CR21","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby, P. J., Silberstein, S. D., Yeung, P. P., Cohen, J. M., Ning, X., Yang, R., & Dodick, D. W. (2020). Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology, 95(18), e2487\u2013e2499. https:\/\/doi.org\/10.1212\/WNL.0000000000010600","journal-title":"Neurology"},{"issue":"1","key":"395_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s10194-020-01177-4","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse, D. C., Gandhi, S. K., Cohen, J. M., Ramirez-Campos, V., Cloud, B., Yang, R., & Cowan, R. P. (2020). Improvements across a range of patient-reported domains with fremanezumab treatment: Results from a patient survey study. The Journal of Headache and Pain, 21(1), 109. https:\/\/doi.org\/10.1186\/s10194-020-01177-4","journal-title":"The Journal of Headache and Pain"},{"issue":"11","key":"395_CR23","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1007\/s12325-023-02671-2","volume":"40","author":"A Antalfy","year":"2023","unstructured":"Antalfy, A., Berman, K., Everitt, C., Alten, R., Latymer, M., & Godfrey, C. M. (2023). The adherence and outcomes benefits of using a connected, reusable auto-injector for self-injecting biologics: A narrative review. Advances in Therapy, 40(11), 4758\u20134776. https:\/\/doi.org\/10.1007\/s12325-023-02671-2","journal-title":"Advances in Therapy"},{"issue":"1","key":"395_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-019-0998-8","volume":"20","author":"R Cowan","year":"2019","unstructured":"Cowan, R., Cohen, J. M., Rosenman, E., & Iyer, R. (2019). Physician and patient preferences for dosing options in migraine prevention. The Journal of Headache and Pain, 20(1), 50. https:\/\/doi.org\/10.1186\/s10194-019-0998-8","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"395_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-023-01552-x","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli, B., Fitzek, M., Overeem, L. H., Storch, E., Terhart, M., & Reuter, U. (2023). Clinical evaluation of super-responders vs non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. The Journal of Headache and Pain, 24(1), 16. https:\/\/doi.org\/10.1186\/s10194-023-01552-x","journal-title":"The Journal of Headache and Pain"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00395-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T14:54:12Z","timestamp":1748962452000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00395-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00395-y","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of Dokkyo Medical University Hospital. The Institutional Review Board of Dokkyo Medical University Hospital waived the requirement for patients to sign informed consent forms on the basis of the retrospective, observational nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. S Suzuki received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen and Otsuka Pharmaceutical Co., Ltd., during the study. K Suzuki received lecture fees from Eli Lilly Japan, Daiichi Sankyo and Otsuka Pharmaceutical Co., Ltd., during the study. Y Haruyama, H Fujita, T Shiina, S Kobayashi, M Shioda and R Hida have nothing to disclose. K Hirata received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen and Otsuka Pharmaceutical Co., Ltd., during the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}